Related Experiment Videos
Therapeutic decision-making in inhibitor patients
Geoffrey Allen1, Louis Aledort
1Pediatric Hematology/Oncology, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7220, USA. allen@med.unc.edu
American Journal of Hematology
|December 22, 2005
Summary
Hematologists discussed hemophilia A treatment with inhibitors, noting challenges with bypassing therapies like NovoSeven and FEIBA. They found low thrombotic risk and emphasized considering cost and non-recombinant options for patient care.
Area of Science:
- Hematology
- Coagulation Disorders
- Internal Medicine
Background:
- Hemophilia A with inhibitors presents complex treatment challenges.
- Managing bleeding episodes requires careful consideration of therapeutic options.
Framework:
- Expert panel discussion on treatment choices for hemophilia A with inhibitors.
- Focus on bypassing therapy efficacy, dosing, and combination use.
- Evaluation of thrombotic risk associated with bypassing agents.
Implementation:
- Variable patient response to bypassing therapy necessitates individualized treatment strategies.
- Uncertainties exist regarding optimal dosing of NovoSeven (eptacog alfa).
- Concerns regarding the combined use of NovoSeven and FEIBA (activated prothrombin complex concentrate) were raised.
Implications:
- Thrombotic risk for NovoSeven and FEIBA was assessed as very low.
- Consensus reached that product selection should not be limited to recombinant products.
- Cost considerations play a significant role in therapeutic decision-making for hemophilia A patients with inhibitors.
Related Concept Videos
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:13Therapeutic Index
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...